Research
Energy balance
To achieve nondominance, the annual price of semaglutide would need to be reduced from $13,618 to $3,591.
This suggests that pricing strategies for semaglutide could significantly impact its adoption in clinical practice.
StrongSupportsmedium confidence
To achieve nondominance, the annual price of semaglutide, currently $13 618, would need to be $3591.
Why this rating
Based on the economic evaluation study design.
Source
Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight Loss
Muhammad Haseeb et al. · JAMA Network Open · 2024
DOI 10.1001/jamanetworkopen.2024.6221
otherCited 66×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Endoscopic sleeve gastroplasty (ESG) is more cost-effective than semaglutide over a 5-year time horizon, with an incremental cost-effectiveness ratio (ICER) of -$595,532/QALY.Strong
- Endoscopic sleeve gastroplasty (ESG) added 0.06 quality-adjusted life-years (QALYs) and reduced total cost by $33,583 relative to semaglutide.Strong
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →